摘要:
Disclosed relates to a method for preparing unsaturated fatty acids and, more particularly, to a method for preparing unsaturated fatty acids in a high purity of at least 99% by isolating and purifying unsaturated fatty acids via a secondary nucleation mechanism using fatty acid-urea inclusion compounds.
摘要:
Disclosed relates to a method for improving a conversion rate of oil soluble unsaturated lipids into water-soluble lipids and, more particularly, to a method for improving a conversion rate of oil soluble unsaturated lipids into water-soluble lipids that forms an unsaturated lipid-chloride derivative having an increased reaction activity by using a pyridine-thionyl chloride as a catalyst, not directly causing a reaction between the unsaturated lipids and amino acids, or that applies an emulsifier to cause a reaction between the unsaturated lipids and amino acids so as to minimize the size of lipid particles to a nano-size of less than 50 nm, thus improving the reaction conversion rate to more than 99%.
摘要:
A plurality of fuel cell stacks (8, 8a, 9, 9a) have their cathode ends (11, 12) contiguous with either a common current collector (15a-15d) or respective current collectors (15a, 15b) which may be separated by electrical isolation (27a, 27b). The cathode-to-cathode relationship protects the cathode of each of the stacks from cold ambient environments, thereby permitting improved cold starts and mitigation of performance loss as a result of cold starts as well as freeze/thaw cycles. Heaters (30, 30a-30d) may be provided in current collectors, or in or between electrical isolation. Four stacks may share one current collector, or each may have its own current collector.
摘要:
The present invention relates to variants of a parent glycoside hydrolase, comprising a substitution at one or more positions corresponding to positions 21, 94, 157, 205, 206, 247, 337, 350, 373, 383, 438, 455, 467, and 486 of amino acids 1 to 513 of SEQ ID NO: 2, and optionally further comprising a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2 a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2, wherein the variants have glycoside hydrolase activity. The present invention also relates to nucleotide sequences encoding the variant glycoside hydrolases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.
摘要翻译:本发明涉及母体糖苷水解酶的变体,其包含在对应于位置21,94,157,205,206,247,337,350,373,383,438,455,467的一个或多个位置的取代,和 486,SEQ ID NO:2的氨基酸1至513,并且任选地还包含在对应于位置8,22,41,49,57,113,193,196,226,227,246,29的一个或多个位置的取代, SEQ ID NO:2的氨基酸1至513的251,255,259,301,356,371,411和462在对应于位置8,22,41,49,57,113, SEQ ID NO:2的氨基酸1至513的193,196,226,227,246,251,255,259,301,356,371,411和462,其中所述变体具有糖苷水解酶活性。 本发明还涉及编码变体糖苷水解酶的核苷酸序列以及包含核苷酸序列的核酸构建体,载体和宿主细胞。
摘要:
The invention relates to novel pyridine derivatives having an inhibitory effect on production of cytokines, which are involved in inflammatory responses, thus suggesting its usefulness as therapeutic agents for treating diseases related to inflammation, immune, chronic inflammation as well as an agent having an anti-inflammatory and analgesic effect. Further, this invention relates to a method of manufacturing the same and a pharmaceutical composition containing the same.
摘要:
The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.
摘要:
The present invention relates to variants of a parent glycoside hydrolase, comprising a substitution at one or more positions corresponding to positions 21, 94, 157, 205, 206, 247, 337, 350, 373, 383, 438, 455, 467, and 486 of amino acids 1 to 513 of SEQ ID NO: 2, and optionally further comprising a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2 a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2, wherein the variants have glycoside hydrolase activity. The present invention also relates to nucleotide sequences encoding the variant glycoside hydrolases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.
摘要翻译:本发明涉及母体糖苷水解酶的变体,其包含在对应于位置21,94,157,205,206,247,337,350,373,383,438,455,467的一个或多个位置的取代,和 486,SEQ ID NO:2的氨基酸1至513,并且任选地还包含在对应于位置8,22,41,49,57,113,193,196,226,227,246,29的一个或多个位置的取代, SEQ ID NO:2的氨基酸1至513的251,255,259,301,356,371,411和462在对应于位置8,22,41,49,57,113, SEQ ID NO:2的氨基酸1至513的193,196,226,227,246,251,255,259,301,356,371,411和462,其中所述变体具有糖苷水解酶活性。 本发明还涉及编码变体糖苷水解酶的核苷酸序列以及包含核苷酸序列的核酸构建体,载体和宿主细胞。
摘要:
Systems and methods are provided for interactions between print servers and mobile phones. One embodiment is a mobile phone comprising a memory, a transceiver, and a control unit. The memory is operable to store rules for interacting with printers, and the transceiver is operable to communicate with a wireless telecommunication network via radio frequency transmissions. The control unit is operable to receive a notification from a print server via the transceiver that indicates status information for a printer controlled by the print server, to determine actions available for the printer based on the stored rules and the status information, and to generate a Graphical User Interface (GUI) that displays interactive graphical elements selectable by a user to initiate the available actions for the printer.
摘要:
The present invention relates to variants of a parent glycoside hydrolase, comprising a substitution at one or more positions corresponding to positions 21, 94, 157, 205, 206, 247, 337, 350, 373, 383, 438, 455, 467, and 486 of amino acids 1 to 513 of SEQ ID NO: 2, and optionally further comprising a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2 a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2, wherein the variants have glycoside hydrolase activity. The present invention also relates to nucleotide sequences encoding the variant glycoside hydrolases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.
摘要:
The present invention relates to variants of a parent glycoside hydrolase, comprising a substitution at one or more positions corresponding to positions 21, 94, 157, 205, 206, 247, 337, 350, 373, 383, 438, 455, 467, and 486 of amino acids 1 to 513 of SEQ ID NO: 2, and optionally further comprising a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2 a substitution at one or more positions corresponding to positions 8, 22, 41, 49, 57, 113, 193, 196, 226, 227, 246, 251, 255, 259, 301, 356, 371, 411, and 462 of amino acids 1 to 513 of SEQ ID NO: 2, wherein the variants have glycoside hydrolase activity. The present invention also relates to nucleotide sequences encoding the variant glycoside hydrolases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.
摘要翻译:本发明涉及母体糖苷水解酶的变体,其包含在对应于位置21,94,157,205,206,247,337,350,373,383,438,455,467的一个或多个位置的取代,和 486,SEQ ID NO:2的氨基酸1至513,并且任选地还包含在对应于位置8,22,41,49,57,113,193,196,226,227,246,29的一个或多个位置的取代, SEQ ID NO:2的氨基酸1至513的251,255,259,301,356,371,411和462在对应于位置8,22,41,49,57,113, SEQ ID NO:2的氨基酸1至513的193,196,226,227,246,251,255,259,301,356,371,411和462,其中所述变体具有糖苷水解酶活性。 本发明还涉及编码变体糖苷水解酶的核苷酸序列以及包含核苷酸序列的核酸构建体,载体和宿主细胞。